OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.
Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.
Read this issue’s cover story titled “Specialists navigate changing, challenging landscape of geographic atrophy management.” ...
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript March 5, 2026 REGENXBIO Inc. misses on earnings expectations. Reported EPS is $-1.3 EPS, expectations were $-1.01. Operator: Thank you for ...
Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) outlined the company’s gene therapy platform, clinical progress, and ...
Detailed price information for Opus Genetics Inc (IRD-Q) from The Globe and Mail including charting and trades.
Hi. Good morning, everyone. I'm Ellie Merle, one of the biotech analysts here at Barclays. Thank you for joining us here in Sunny Miami. Very happy to have 4D Molecular Therapeutics here with us today ...
Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to ...
Some patients taking popular GLP-1 weight loss drugs may be able to keep the weight off while taking injections less often, according to a small new study. The idea began when Dr. Mitch Biermann, an ...
The idea behind intra-articular gene therapy for treating osteoarthritis (OA) is to deliver the gene-altering vector or cells directly to the precise site of the disease with a single injection — so ...
Share on Pinterest A small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections. Image Credit: Siluk/UCG/Universal Images Group via Getty Images A recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results